CryoPort Reports Successful Pilot Shipments for Multiple Pharmaceutical Companies

BREA, CA -- (MARKET WIRE) -- 04/23/07 -- CryoPort, Inc. (PINKSHEETS: CYRX) announced today that it has successfully completed pilot shipments of the CryoPort Express® One Way Shipper System involving medicines and biomaterials with selected pharmaceutical manufacturers.

The shipments included such destinations as Thailand and India. In addition, research biomaterials are currently shipping to South Africa. CryoPort's CEO, Mr. Peter Berry, commented, "These successful pilot shipments are particularly significant as they confirm the application of our one-way technology in shipping to locations that have historically provided significant challenges for cold chain shipments within global clinical trials. Due to the sensitivity of R&D activities within the pharmaceutical sectors, we are not able to discuss the names of our pilot partners at this time, although I am hopeful that as their programs mature we will be able to share this information with our investors."

Mr. Berry concluded, "As our pilot program partners continue to increase their usage of the CryoPort Express® platform, we are responding by taking the initial steps to establish a foundation for ramping up our manufacturing to a larger scale in an effort to meet the anticipated demand for our products."

Additional information on CryoPort, including a downloadable Investor Fact Sheet, can be found at

About CryoPort, Inc.

CryoPort ( develops leading edge, proprietary, technology driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical sectors. The products are essential components of the infrastructure required for the testing, research and end user delivery components that make up the foundation of the biopharmaceutical and biotechnology industries.


This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Investor Relations:
First Capital Investors, Inc.
Email Contact